Corrigendum to "Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome" [Cytokine 35 (2006) 21-28] (DOI:10.1016/j.cyto.2006.07.003);Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome

Cytokine

Volumn 35, Issue 1-2, 2006, Pages 21-28

  Sfar, Sana ^a   Hassen, Elham ^a   Saad, Hamadi ^b   Mosbah, Faouzi ^c   Chouchane, Lotfi ^a  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b FATTOUMA BOURGUIBA UNIVERSITY HOSPITAL   (Tunisia)

^c SAHLOUL UNIVERSITY HOSPITAL   (Tunisia)

Author keywords

Genetic susceptibility; Polymorphism; Prognosis; Prostate carcinoma; VEGF

Indexed keywords

VASCULOTROPIN;

ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; RISK FACTOR;

EID: 33749267776     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2006.11.009     Document Type: Erratum

References (59)

1. ACS. Cancer Facts and figures. Atlanta: American Cancer Society; 2004.
2. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., Feuer E.J., and Thun M.J. Cancer statistics. CA Cancer J Clin 55 1 (2005) 10-30
3. Jemal A., Tiwari R.C., Murray T., Ghafoor A., Samuels A., Ward E., Feuer E.J., and Thun M.J. American Cancer Society. Cancer statistics. CA Cancer J Clin 54 1 (2004) 8-29
4. Shields P.G., and Harris C.C. Cancer risk and low-penetrance susceptibility genes in gene-environment interactions. J Clin Oncol 18 11 (2000) 2309-2315
5. Lichtenstein P., Holm N.V., Verkasalo P.K., Iliadou A., Kaprio J., Koskenvuo M., et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343 2 (2000) 78-85
6. Carter B.S., Bova G.S., Beaty T.H., Steinberg G.D., Childs B., Isaacs W.B., et al. Hereditary prostate cancer: epidemiologic and clinical features. J Urol 150 3 (1993) 797-802
7. Catalona W.J., Smith D.S., Ratliff T.L., and Basler J.W. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 270 8 (1993) 948-954
8. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 147 (1995) 9-19
9. Ellis L.M., and Fidler I.J. Angiogenesis and metastasis. Eur J Cancer 32 14 (1996) 2451-2460
10. Weidner N., Carroll P.R., Flax J., Blumenfeld W., and Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143 2 (1993) 401-409
11. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial Award lecture. Cancer Res 46 2 (1986) 467-473
12. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
13. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., and Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246 4935 (1989) 1306-1309
14. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., and Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219 4587 (1983) 983-985
15. Grunstein J., Roberts W.G., Mathieu-Costello O., Hanahan D., and Johnson R.S. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res 59 7 (1999) 1592-1598
16. Carmeliet P., Ferreira V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M., et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380 6573 (1996) 435-439
17. Veikkola T., Karkkainen M., Claesson-Welsh L., and Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 60 2 (2000) 203-212
18. Neufeld G., Cohen T., Gengrinovitch S., and Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13 1 (1999) 9-22
19. Millauer B., Shawver L.K., Plate K.H., Risau W., and Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367 6463 (1994) 576-579
20. Ferrer F.A., Miller L.J., Lindquist R., Kowalczyk P., Laudone V.P., Albertsen P.C., et al. Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 54 3 (1999) 567-572
21. Jackson M.W., Roberts J.S., Heckford S.E., Ricciardelli C., Stahl J., Choong C., et al. A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res 62 3 (2002) 854-859
22. Steiner H., Berger A.P., Godoy-Tundidor S., Bjartell A., Lilja H., Bartsch G., et al. An autocrine loop for vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin 6. Eur J Cancer 40 7 (2004) 1066-1072
23. Oyama T., Ran S., Ishida T., Nadaf S., Kerr L., Carbone D.P., et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol 160 3 (1998) 1224-1232
24. Ohm J.E., and Carbone D.P. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res 23 2-3 (2001) 263-272
25. Dikov M.M., Ohm J.E., Ray N., Tchekneva E.E., Burlison J., Moghanaki D., et al. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J Immunol 174 1 (2005) 215-222
26. Dikov M.M., Oyama T., Cheng P., Takahashi T., Takahashi K., Sepetavec T., et al. Vascular endothelial growth factor effects on nuclear factor-kappaB activation in hematopoietic progenitor cells. Cancer Res 61 5 (2001) 2015-2021
27. Gabrilovich D.I., Corak J., Ciernik I.F., Kavanaugh D., and Carbone D.P. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 3 3 (1997) 483-490
28. Gabrilovich D.I., Ishida T., Oyama T., Ran S., Kravtsov V., Nadaf S., et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92 11 (1998) 4150-4166
29. Ohm J.E., Gabrilovich D.I., Sempowski G.D., Kisseleva E., Parman K.S., Nadaf S., et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 101 12 (2003) 4878-4886
30. Vincenti V., Cassano C., Rocchi M., and Persico G. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 93 8 (1996) 1493-1495
31. Watson C.J., Webb N.J., Bottomley M.J., and Brenchley P.E. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12 8 (2000) 1232-1235
32. Shahbazi M., Fryer A.A., Pravica V., Brogan I.J., Ramsay H.M., Hutchinson I.V., et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 13 1 (2002) 260-264
33. Koukourakis M.I., Papazoglou D., Giatromanolaki A., Bougioukas G., Maltezos E., and Sivridis E. VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 46 3 (2004) 293-298
34. Lambrechts D., Storkebaum E., Morimoto M., Del-Favero J., Desmet F., Marklund S.L., et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 34 (2003) 383-394
35. Brogan I.J., Khan N., Isaac K., Hutchinson J.A., Pravica V., and Hutchinson I.V. Novel polymorphisms in the promoter and 5′ UTR regions of the human vascular endothelial growth factor gene. Hum Immunol 60 12 (1999) 1245-1249
36. Renner W., Kotschan S., Hoffmann C., Obermayer-Pietsch B., and Pilger E. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 37 6 (2000) 443-448
37. Stevens A., Soden J., Brenchley P.E., Ralph S., and Ray D.W. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 63 (2003) 812-816
38. Awata T., Inoue K., Kurihara S., Ohkubo T., Watanabe M., Inukai K., et al. A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 51 5 (2002) 1635-1639
39. Awata T., Kurihara S., Takata N., Neda T., Iizuka H., Ohkubo T., et al. Functional VEGF C-634G polymorphism is associated with development of diabetic macular edema and correlated with macular retinal thickness in type 2 diabetes. Biochem Biophys Res Commun 333 3 (2005) 679-685
40. Ferrer F.A., Miller L.J., Andrawis R.I., Kurtzman S.H., Albertsen P.C., Laudone V.P., and Kreutzer D.L. Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 51 1 (1998) 161-167
41. Duque J.L., Loughlin K.R., Adam R.M., Kantoff P.W., Zurakowski D., and Freeman M.R. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 54 3 (1999) 523-527
42. Bok R.A., Halabi S., Fei D.T., Rodriquez C.R., Hayes D.F., Vogelzang N.J., et al. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res 61 6 (2001) 2533-2536
43. Cascinu S., Graziano F., Valentini M., Catalano V., Giordani P., Staccioli M.P., et al. Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapy. Ann Oncol 12 2 (2001) 239-244
44. Sato K., Sasaki R., Ogura Y., Shimoda N., Togashi H., Terada K., et al. Expression of vascular endothelial growth factor gene and its receptor (flt-1) gene in urinary bladder cancer. Tohoku J Exp Med 185 3 (1998) 173-184
45. Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 5 Suppl 1 (2000) 37-44
46. Miller S.A., Dykes D.D., and Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16 (1988) 1215
47. McCarron S.L., Edwards S., Evans P.R., Gibbs R., Dearnaley D.P., Dowe A., et al. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 62 12 (2002) 3369-3372
48. Stephens M., Smith N.J., and Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68 (2001) 978-989
49. Smith K.C., Bateman A.C., Fussell H.M., and Howell W.M. Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur J Immunogenet 31 4 (2004) 167-173
50. Howell W.M., Bateman A.C., Turner S.J., Collins A., and Theaker J.M. Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumor development in cutaneous malignant melanoma. Genes Immun 3 4 (2002) 229-232
51. Mazzucchelli R., Montironi R., Santinelli A., et al. Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. Prostate 45 (2000) 72-79
52. Jin Q., Hemminki K., Enquist K., Lenner P., Grzybowska E., Klaes R., et al. Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res 11 10 (2005) 3647-3653
53. Lee S.J., Lee S.Y., Jeon H.S., Park S.H., Jang J.S., Lee G.Y., et al. Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev 14 3 (2005) 571-575
54. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77 7 (1999) 527-543
55. Brown L.F., Detmar M., Claffey K., Nagy J.A., Feng D., Dvorak A.M., and Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS 79 (1997) 233-269
56. Garcia-Cardena G., and Folkman J. Is there a role for nitric oxide in tumor angiogenesis?. J Natl Cancer Inst 90 8 (1998) 560-561
57. Lu H., Shu X.O., Cui Y., Kataoka N., Wen W., Cai Q., et al. Association of genetic polymorphisms in the VEGF gene with breast cancer survival. Cancer Res 65 12 (2005) 5015-5019
58. Abe A., Sato K., Habuchi T., Wang L., Li Z., Tsuchiya N., Ohyama C., Satoh S., Ogawa O., and Kato T. Single nucleotide polymorphisms in the 3′ untranslated region of vascular endothelial growth factor gene in Japanese population with or without renal cell carcinoma. Tohoku J Exp Med 198 3 (2002) 181-190
59. Krippl P., Langsenlehner U., Renner W., Yazdani-Biuki B., Wolf G., Wascher T.C., et al. A common 936 C/T gene polymorphism of vascular endothelial growth is associated with decreased breast cancer risk. Int J Cancer 106 4 (2003) 468-471